Literature DB >> 16088469

Leprosy of the past and today.

John M Grange1, Julie I Lethaby.   

Abstract

Despite enhanced disease control efforts, leprosy remains an important cause of disability in several countries. Being based on case detection, the exact prevalence of the disease is not easily estimated. Currently around 600,000 new cases are treated annually. Advances in immunology and molecular biology have led to a greater understanding of the disease and to hopes for improved diagnostic tests and vaccination strategies. The major advance, though, is the development of highly effective combination drug regimens which, provided all doses are taken, rarely fails to cure. The challenge to leprosy control services is to overcome the stigma associated with the disease so that patients present with minimal lesions and before disabilities have developed. Although it is hoped that leprosy as a serious public health problem will be eliminated within a few years, continuing care for those suffering from deformity and rejection by society will be required for several decades.

Entities:  

Year:  2004        PMID: 16088469     DOI: 10.1055/s-2004-829500

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  2 in total

1.  Anti-cyclic citrullinated peptide antibodies and rheumatoid factor sera titers in leprosy patients from Mexico.

Authors:  María G Zavala-Cerna; Mary Fafutis-Morris; Cecilia Guillen-Vargas; Mario Salazar-Páramo; Diana E García-Cruz; Carlos Riebeling; Arnulfo Nava
Journal:  Rheumatol Int       Date:  2011-11-15       Impact factor: 2.631

2.  Interferon-gamma receptor-1 gene promoter polymorphisms and susceptibility to leprosy in children of a single family.

Authors:  Ali A Velayati; Parissa Farnia; Soheila Khalizadeh; Amir M Farahbod; Maryam Hasanzadh; Maryam F Sheikolslam
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.